Increased Serum Levels of High-mobility Group Box 1 Protein in Patients Who Developed Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Overview
Authors
Affiliations
Inflammasomes: potential therapeutic targets in hematopoietic stem cell transplantation.
Luo J, Zhou Y, Wang M, Zhang J, Jiang E Cell Commun Signal. 2024; 22(1):596.
PMID: 39695742 PMC: 11657697. DOI: 10.1186/s12964-024-01974-3.
Nomura S, Ichikawa J, Shimizu T, Ishiura Y, Okada M, Ishii K Clin Appl Thromb Hemost. 2023; 29:10760296231193398.
PMID: 37563884 PMC: 10422918. DOI: 10.1177/10760296231193398.
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies.
Yuan S, Liu Z, Xu Z, Liu J, Zhang J J Hematol Oncol. 2020; 13(1):91.
PMID: 32660524 PMC: 7359022. DOI: 10.1186/s13045-020-00920-3.
Ferrara J, Smith C, Sheets J, Reddy P, Serody J J Clin Invest. 2017; 127(7):2441-2451.
PMID: 28581444 PMC: 5490758. DOI: 10.1172/JCI90592.
Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives.
Toubai T, Mathewson N, Magenau J, Reddy P Front Immunol. 2016; 7:539.
PMID: 27965667 PMC: 5126092. DOI: 10.3389/fimmu.2016.00539.